BioCentury
ARTICLE | Clinical News

Ardelyx gains on Phase IIb IBS-C data

October 2, 2014 2:57 AM UTC

Ardelyx Inc. (NASDAQ:ARDX) jumped $4.79 (34%) to $19 on Wednesday after 50 mg tenapanor ( RDX5791/ AZD1722) met the primary endpoint of increasing complete spontaneous bowel movement (CSBM) responder rate in a Phase IIb trial to treat constipation predominant irritable bowel syndrome (IBS-C).

The small molecule inhibitor of non-absorbed solute carrier family 9 sodium hydrogen exchanger member 3 ( SLC9A3; NHE3) resulted in a 60.7% CSBM responder rate in patients receiving 50 mg tenapanor twice daily vs. 33.7% in those receiving placebo over 12 weeks. Two other dosages tested -- 5 mg and 20 mg -- missed the primary endpoint. ...